文献速递造血干细胞移植与细胞治疗

高血糖可预测异基因造血干细胞移植患者的并发症与死亡

Hyperglycaemia as a predictor of morbidity and mortality in patients receiving an allogeneic haematopoietic stem cell transplantation.
PubMed 文献 · Br J Haematol · 2026-07-17

荷兰格罗宁根大学医学中心2018至2024年回顾性纳入575例接受异基因造血干细胞移植的成人患者,高血糖定义为毛细血管或静脉血糖超过10 mmol/L。住院期间26.6%患者至少出现一次高血糖,校正混杂因素后高血糖与100天总生存显著降低、重度aGvHD及感染风险升高相关,移植前30天内出现的高血糖也已预示更差生存。

要点

  • allo-HSCT住院期间26.6%患者至少发生一次血糖超过10 mmol/L的高血糖。
  • 校正混杂后高血糖与100天总生存降低相关(HR 2.36,95%CI 1.29-4.33)。
  • 高血糖与重度(≥3级)aGvHD及感染风险升高相关,移植前30天出现即已提示预后不良。

核心结论

  • allo-HSCT期间任一时刻的高血糖均可预测治疗相关不良事件,因血糖高度可调控,密切关注与及时干预或可改善结局。

研究设计与样本

  • 单中心回顾性研究,纳入2018至2024年在格罗宁根大学医学中心接受allo-HSCT的成人患者共575例。
  • 高血糖定义为毛细血管或静脉样本血糖水平超过10 mmol/L。

主要发现

  • 患者中位年龄61岁(IQR 52-68),男性占64%,中位BMI为25.3 kg/m2(IQR 23.1-28.0)。
  • 住院期间26.6%的患者至少经历一次高血糖。
  • 校正混杂变量后,高血糖与100天总生存显著降低相关(HR 2.36,95%CI 1.29-4.33)。
  • 高血糖还与重度(≥3级)aGvHD及感染风险升高相关。
  • 移植前30天内发生的高血糖已可预测更差的生存。

临床怎么用

  • 对allo-HSCT患者应关注血糖监测,移植前30天至住院全程的高血糖均需重视并及时干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for patients with haematological malignancies; however, post-transplant complications, including infections and acute graft-versus-host disease (aGvHD), remain significant issues. Identifying modifiable risk factors is therefore critical to improve patient outcomes. This retrospective study evaluated the impact of hyperglycaemia on post-transplant outcomes in adult patients undergoing allo-HSCT at the University Medical Centre Groningen between 2018 and 2024. Hyperglycaemia was defined as a glucose level exceeding 10 mmol/L in capillary or venous samples. In total, 575 patients were included. The median age was 61 years (interquartile range [IQR]: 52-68); 64% were male, and the median body mass index (BMI) was 25.3 kg/m2 (IQR: 23.1-28.0). During hospitalization, 26.6% of patients experienced at least one episode of hyperglycaemia. After adjusting for confounding variables, hyperglycaemia was associated with significantly reduced 100-day overall survival (hazard ratio [HR] 2.36, 95% confidence interval [CI] 1.29-4.33). It was also linked to an increased risk of severe (grade ≥3) aGvHD and infections. Importantly, hyperglycaemia occurring within 30 days prior to transplantation already predicted poorer survival. In conclusion, hyperglycaemia at any moment during allo-HSCT is predictive for treatment-related adverse events. Since glucose levels are highly modifiable, closer attention and timely intervention might improve outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Tienstra M, Goemans FR, Keijzer K, et al. Hyperglycaemia as a predictor of morbidity and mortality in patients receiving an allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2026. PMID: 42466873. doi:10.1111/bjh.70692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。